secwatch / observer
8-K filed May 8, 2023, 7:59 PM ET ticker AKBA CIK 0001517022
other material confidence high sentiment negative materiality 0.60

Akebia shareholders reject 1-for-5 to 1-for-20 reverse stock split at special meeting

Akebia Therapeutics, Inc.

Key facts

Extracted from this filing and checked against the source text.

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Akebia Therapeutics, Inc. shareholders rejected Approval of an amendment to the Ninth Amended and Restated Certificate of Incorporation to decrease the number of authorized shares of Common Stock on a basis proportional to the reverse stock split ratio. at the 2023-05-04 meeting.

Proposal
charter amendment
Outcome
failed
Meeting
2023-05-04
Exact text from the filing
The proposal to, in connection with Proposal 1(a), decrease the number of authorized shares of the Company’s Common Stock on a basis proportional to the reverse stock split ratio (“Proposal 1(b)” and, together with Proposal 1(a), the “Reverse Stock Split Proposals”) was not approved as follows: Votes For: 78,473,738 Votes Against: 54,949,341 Abstentions: 647,283
View on SEC.gov
Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Akebia Therapeutics, Inc. shareholders rejected Approval of an amendment to the Ninth Amended and Restated Certificate of Incorporation to effect a reverse stock split of Common Stock at a ratio of not less than 1-for-5 and not greater than 1-for-20, with the exact ratio to be set at the discretion of the Board of Directors. at the 2023-05-04 meeting.

Proposal
reverse split
Outcome
failed
Meeting
2023-05-04
Exact text from the filing
The proposal to approve an amendment to the Company’s Ninth Amended and Restated Certificate of Incorporation, as amended, to effect a reverse stock split of the Company’s outstanding common stock, $0.00001 par value per share (the “Common Stock”), at a ratio of not less than 1-for-5 and not greater than 1-for-20, with the exact ratio to be set within that range at the discretion of the Company’s Board of Directors, at any time prior to the one-year anniversary of the date on which the reverse stock split is approved by the Company’s stockholders at the Special Meeting (“Proposal 1(a)”), was not approved as follows: Votes For: 77,934,578 Votes Against: 57,085,942 Abstentions: 563,365
View on SEC.gov
Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Akebia Therapeutics, Inc. shareholders approved Approval of an adjournment of the Special Meeting to a later date or dates, if necessary or appropriate, to permit further solicitation and vote of proxies in the event that there are insufficient votes for, or otherwise in connection with, the approval of either of the Reverse Stock Split Proposals at the 2023-05-04 meeting.

Proposal
reverse split
Outcome
passed
Meeting
2023-05-04
Exact text from the filing
The proposal to approve an adjournment of the Special Meeting to a later date or dates, if necessary or appropriate, to permit further solicitation and vote of proxies in the event that there are insufficient votes for, or otherwise in connection with, the approval of either of the Reverse Stock Split Proposals (Proposal 1(a) or 1(b)) was approved as follows: Votes For: 77,956,153 Votes Against: 56,291,429 Abstentions: 1,336,302 Broker Non-Votes 0
View on SEC.gov

Browse all shareholder votes →

Akebia Therapeutics, Inc. filing history →

Source: SEC EDGAR
accession 0001193125-23-137688
Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.